Skip to main content
Clinical Trials/NCT00432939
NCT00432939CompletedNot Applicable

Primary Hyperparathyroidism: Non-classical Manifestations

Columbia University1 site in 1 country58 target enrollmentStarted: October 2005Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
58
Locations
1
Primary Endpoint
Structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT

Study Overview

Brief Summary

This is a research study to investigate cardiovascular health in people with mild hyperparathyroidism. Previous research has suggested that severe hyperparathyroidism may be associated with abnormalities in the heart and blood vessels. It is unclear whether mild hyperparathyroidism affects cardiovascular health. This study involves the investigation of the heart and blood vessels of people with mild hyperparathyroidism. Various non-invasive laboratory and radiological test to assess cardiovascular and bone health will be done at set intervals over the course of 2 years. It is our hypothesis that patients with primary hyperparathyroidism will have subtle abnormalities in their cardiovascular system. Using state-of-the art techniques that are sufficiently sensitive to detect these subtle abnormalities, we will define cardiovascular features of this disease that have, up to now, eluded clear definition. We expect taht the extent of these findings will be related to the severity of the underlying primary hyperparathyroidism. We further hypothesize that cardiovascular manifestations may regress with successful cure of the hyperparathyroid state.

Detailed Description

This study involves a total of 4 visits over a 2-year period. A variety of tests to evaluate your cardiovascular and bone health are performed. The details and timing of the tests are explained below.

VISIT #1 During the first visit, a research doctor or assistant explains the procedures in detail and answers questions. Blood is drawn (about 1-2 tablespoons) to confirm the diagnosis of hyperparathyroidism and get baseline blood values.

VISIT #2-4 During the following visits, a variety of procedures are performed to evaluate cardiovascular and bone health. The details of the procedures and when they will be performed are outlined below.

  1. Blood tests are performed at each visit. Approximately 1-2 tablespoons of blood will be drawn at each visit.
  2. A 24-hour urine collection is done 3 times during the 2 year study.
  3. Bone mineral density testing (known as DXA) is performed at baseline, 12 and 24 months after enrollment.
  4. Carotid Ultrasound: At the baseline visit, 12 and 24 months after enrollment, carotid ultrasound is performed.
  5. Echocardiogram: At the baseline visit, 12 and 24 months after enrollment, an echocardiogram is performed.
  6. Endothelial Function: At baseline, 6 and 12 months after enrollment, flow mediated dilation of the brachial artery is performed.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
50 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Primary Hyperparathyroidism

Exclusion Criteria

  • Current use of oral bisphosphonates
  • Addition or change in cholesterol lowering medication
  • impaired renal function (creatinine >2.0 mg/dl)

Outcomes

Primary Outcomes

Structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT

Time Frame: 2 years

To determine whether or not there is structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT as compared to matched healthy controls, and to determine the reversibility of these manifestations after successful parathyroidectomy

Secondary Outcomes

  • Evidence of abnormal cardiovascular function in patients with mild asymptomatic PHPT(2 years)
  • Evidence of abnormal cardiovascular structure or function in patients with asymptomatic PHPT who meet NIH Guidelines for Surgery(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Shonni J. Silverberg

Professor of Medicine, Endocrinology

Columbia University

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Effect of Parathyroidectomy on Cardiovascular HealthPrimary Hyperparathyroidism
NCT02989428University of Aarhus69
Active, not recruiting
Phase 1
Primary hyperparathyroidism: does a systematic treatment improve the calcium and bone metabolism after successful surgery? – Part IISystematic treatment of patients with neither osteopenia nor osteoporosis after successful surgical treatment for primary hyperparathyroidism with Calcium and Vitamin DHypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents hungry bone- syndrome and improve bone-turnover markers (osteoporosis protection).MedDRA version: 9.1Level: LLTClassification code 10020707Term: Hyperparathyroidism primary
EUCTR2008-001704-23-ATMedizinische Universität Wien, Universitätsklinik für Chirurgie80
Active, not recruiting
Phase 1
Primary hyperparathyroidism: does a systematic treatment improve the calcium- and bone metabolism after successful surgery? – Part Systematic treatment of osteopenic and osteoporotic postmenopausal patients after successful surgical treatment for primary hyperparathyroidism with Strontium ranelateOsteopenia or Osteoporosis in postmenopausal womenPrimary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020707Term: Hyperparathyroidism primaryMedDRA version: 9.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausal
EUCTR2008-001703-32-ATMedical University of Vienna60
Completed
Not Applicable
Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized TrialPrimary Hyperparathyroidism
NCT00522028Oslo University Hospital191
Completed
Phase 2
Studies of Elevated Parathyroid ActivityParathyroid NeoplasmMultiple Endocrine NeoplasiaMEN1HyperparathyroidismHypercalcemia
NCT00001277National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,553